Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
Further lowering of low-density lipoprotein (LDL) cholesterol (LDL-C) levels in patients with already low LDL-C produced benefit in terms of reduced risk for major vascular events with no serious adverse effects, a large meta-analysis suggests.
Source: JAMA Cardiology
Related stories
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023
- New SNOMED Codes for FH DNA test results!
- Healthcare Professional Dietary Survey Prize Draw 2022
- Opportunity to join the NICE CG181 guideline committee
- NICE launches review of methods and processes for health technology evaluation
- The Essential Cholesterol Programme for Primary Care
- Add on to take back control. Do we have the solutions to the gaps in our lipid treatment pathway?
- Familial Hypercholesterolaemia: from Epidemiology to Genetics – a paradigm shift?